Walter Robinson’s Post

🔍 Did you know disparities exist in ovarian cancer clinical trial participation? Our latest blog post sheds light on this issue and explores ways to bridge the gap. 𝑻𝒐𝒈𝒆𝒕𝒉𝒆𝒓, 𝒘𝒆 𝒄𝒂𝒏 𝒎𝒂𝒌𝒆 𝒂 𝒄𝒉𝒂𝒏𝒈𝒆. Insightful Read ➡️ https://lnkd.in/eFjCKAQm #ResearchEquality #HealthcareAccess #WCRF

Today, on #WorldCancerDay, honor those battling cancer, raise awareness about early detection, and invest in medical research to find a cure. Everyone has a part to play in the global fight against cancer. Together, we can and will make a difference. #fightcancer #worldcancerawarenessday #medicalresearch #donateblood #savelives #cellularlifesolutions

The American Society of Clinical Oncology (ASCO) Annual Meeting is an important event in the oncology field, bringing together top researchers, trialists and clinicians to discuss groundbreaking cancer research and innovative therapies. Held from May 31 to June 4, 2024, in Chicago, this year’s meeting continues to highlight significant advancements, with respect to newer therapies and newer approaches in cancer care. Whether it was newer therapies, the use of previously unused combinations or investigative approaches like ctDNA, it had’em all. However, it’s crucial to make such influential events more accessible to professionals from low to middle-income countries (LMICs). Providing scholarships, virtual attendance options, and enhanced partnerships can bridge the gap, ensuring broader participation and fostering global collaboration in the fight against cancer. By expanding opportunities for all, we can drive forward the mission of health for all. #ASCO2024 #Oncology #CancerResearch #GlobalHealth

Are you aware of the current real-time statistics on the burden of cancer as of 2022❓ Let's collaborate and take small steps together to reduce the incidence of cancer✨ #SRMSPH #SRMIST #didyouknow

YouScript President and Founder, Kristine Ashcraft, coauthored a landmark paper about how the barriers to PGx testing, discovery, and implementation hinder #PGx adoption and create disparities in diverse populations. Read the full press release from American Cancer Society Cancer Action Network (ACS CAN): https://lnkd.in/d97cfDyW #pharmacogenomics #ACSCAN #precisionmedicine #youscript

🎗✨ In the world cancer day, we must encourage ourselves and our closest ones to make continous check up for early detection, early detection is very crucial for managing any cancer type leading to high cure rate, help us spread the awareness about how early detection save lives. #worldcancerday #cancerfighter #closethecaregap #earlydetection #hopeforacure #cancerawareness #cancerprevention #hopefortomorrow #learningandgrowing #oncologyresearch

This weekend, the American Society of Clinical Oncology (ASCO) conference showcased ground-breaking advancements in the treatment of leukaemia and other haematological malignancies as well as a host of other cancers. A pivotal Phase 3 trial (the ASC4FIRST study) was presented, comparing the first in class drug asciminib with other tyrosine kinase inhibitors (TKIs) in newly diagnosed chronic myeloid leukaemia (CML) patients. The promising results provide evidence that asciminib could become potentially become a first-line treatment in CML, although longer- term follow up data will be needed first. Currently asciminib is available to certain CML patients if other two or more other TKIs have been tried first. Additionally, significant progress was showcased at ASCO in hematopoietic stem cell transplants. A Phase 1 study of STC-15, a METTL-3 inhibitor, showed encouraging results in patients with advanced malignancies, demonstrating safety and clinical activity. This lays the groundwork for Phase 2 trials later this year. Leukaemia UK has funded Dr Kostas Tzelepis's laboratory research at Cambridge on targeting METTL-3 in leukaemia in collaboration with STORM Therapeutics, which led this new trial. We are proud to support such pioneering laboratory work, which could help to underpin the development of potential new leukaemia treatments. https://lnkd.in/eQ3n8GnS #ASCO2024 #LeukemiaResearch #Oncology #Hematology #CancerTreatment #ClinicalTrials #InnovationInHealthcare

This groundbreaking research brings new hope to patients with appendix cancer, offering promising treatment options where there were few before. As studies progress, patients and families can expect more effective, personalized care. More at https://lnkd.in/dSSgQRcc #AppendixCancer #CancerResearch #NewHope #PersonalizedMedicine #TargetedTherapy #MedicalBreakthrough #CancerCare 🌟🧬💊

As we navigate the intricate terrain of blood cancer, ongoing research and active participation in clinical trials serve as beacons of hope. These endeavors pave the way for the continual evolution of treatment options, unlocking new doors to better outcomes and improved lives for those bravely facing the challenges of blood cancer. Together, through scientific exploration and unwavering commitment, we strive to unravel the mysteries and forge a path toward a brighter, healthier future. More at https://lnkd.in/dXV5qk7W #BloodCancerAwareness #CancerTreatment #LeukemiaFight #LymphomaWarriors #MyelomaResearch #AdvancedTherapies #SurvivorJourney #ImmunotherapyBreakthrough #StemCellTransplant #TargetedTherapy #ResearchForACure #CancerSurvivorship #HealthAndWellness #ClinicalTrials #BloodCancerSupport #FightCancerTogether #PrecisionMedicine #HopeInTreatment #QualityOfLife #UnlockingMysteries

Early detection is the key to preserving those cherished times. Let's pledge to #DetectToProtect on World Cancer Day and change the narrative. #DetectToProtect #WorldCancerDay #FortisHospital #FortisCares #EarlyDetection #CancerAwareness #AtFortisWeCare #CareForGood